newsfilter
← Latest News
GlobeNewswire·

Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update

– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV + human